Reports for NATCO PHARMA (CANADA) INC
Company Name
NATCO PHARMA (CANADA) INC
Totals |
||
Shortage reports |
26 |
|
| Actual shortage: | 10 (38%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 0 (0%) | |
| Resolved: | 16 (62%) | |
Discontinuation Reports |
0 |
|
| To be discontinued: | 0 | |
| Discontinued: | 0 | |
| Reversed: | 0 | |
Late reports |
1 (4%) |
|
Overdue reports |
5 (50%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| NAT-ERLOTINIB | 150MG | TABLET | Actual shortage | 2020-12-03 | 2024-02-02 | 129553 |
| NAT-EVEROLIMUS | 2.5MG | TABLET | Actual shortage | 2024-04-29 | 2024-04-30 | 226575 |
| NAT-MONTELUKAST | 4MG | TABLET (CHEWABLE) | Actual shortage | 2024-04-29 | 2024-04-30 | 226579 |
| NAT-MONTELUKAST | 5MG | TABLET (CHEWABLE) | Actual shortage | 2024-04-29 | 2024-04-30 | 226582 |
| NAT-RIZATRIPTAN ODT | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2018-11-23 | 2019-02-07 | 67512 |
| NAT-RIZATRIPTAN ODT | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2018-11-23 | 2019-02-07 | 67515 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|
Showing 1 to 0 of 0